{"id":"gradual-dose-reduction-of-semaglutide","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Weight rebound"},{"rate":null,"effect":"Hyperglycemia rebound"}]},"_chembl":{"chemblId":"CHEMBL4752331","moleculeType":"Unknown","molecularWeight":"4113.64"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Semaglutide is a GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, and slows gastric emptying to lower blood glucose and promote weight loss. This Phase 3 trial examines whether gradual dose reduction preserves therapeutic benefits or leads to rebound weight gain and metabolic deterioration, informing optimal long-term treatment strategies.","oneSentence":"Gradual dose reduction of semaglutide investigates the effects of tapering a GLP-1 receptor agonist to assess weight maintenance, metabolic outcomes, and safety upon discontinuation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:14.198Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Weight management and metabolic outcomes following gradual semaglutide dose reduction"},{"name":"Assessment of weight rebound and glycemic control post-tapering in obese or overweight patients"}]},"trialDetails":[{"nctId":"NCT07294950","phase":"PHASE3","title":"Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2026-02-01","conditions":"Obesity (Disorder), Weight Change, Blood Pressure Monitoring","enrollment":98}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Gradual dose reduction of semaglutide","genericName":"Gradual dose reduction of semaglutide","companyName":"Mount Sinai Hospital, Canada","companyId":"mount-sinai-hospital-canada","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gradual dose reduction of semaglutide investigates the effects of tapering a GLP-1 receptor agonist to assess weight maintenance, metabolic outcomes, and safety upon discontinuation. Used for Weight management and metabolic outcomes following gradual semaglutide dose reduction, Assessment of weight rebound and glycemic control post-tapering in obese or overweight patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}